Approved indications: Dojolvi is FDA‑approved as a source of calories and fatty acids for adults and pediatric patients with molecularly confirmed long‑chain fatty acid oxidation disorders (LC‑FAOD), including defects such as CPT I/II, CACT, VLCAD, TFP, and LCHAD, used alongside diet and other standard measures.

Off‑label uses: Triheptanoin has been explored in small studies and case reports for other rare metabolic and neurologic conditions (for example certain epilepsies and pyruvate carboxylase deficiency), but these uses are investigational, not FDA‑approved, and evidence is limited.

Efficacy expectations: In LC‑FAOD, Dojolvi does not cure the underlying genetic defect but is intended to lower the frequency and severity of events such as hypoglycemia, rhabdomyolysis, liver crises, and cardiomyopathy, with benefits generally evaluated over months by tracking metabolic crises, hospitalizations, energy level, and exercise tolerance.

Comparison to other therapies: Compared with standard even‑chain medium‑chain triglyceride (MCT) oils, triheptanoin supplies both energy and “anaplerotic” substrates for the energy cycle; observational data suggest fewer major clinical events versus historical care, while a short head‑to‑head trial with trioctanoin showed broadly similar short‑term outcomes, so individual response and tolerability guide choice.

Typical dosing and how to take it: The dose is individualized based on daily caloric needs, with a usual target of up to 35% of total daily calories from Dojolvi, divided into at least four doses per day and mixed thoroughly into soft food, drink, or medical formula taken with meals or snacks; treatment is usually started at a lower percentage of calories (such as about 10%) and increased every few days as tolerated, under the guidance of a metabolic specialist.

Special dosing instructions: Stop other medium‑chain triglyceride (MCT) oils before starting Dojolvi; measure doses with an oral syringe or measuring cup made of compatible materials (such as glass, stainless steel, or non‑PVC plastics), never with polystyrene or PVC; if given through a feeding tube, use silicone or polyurethane tubes, mix Dojolvi well into formula or medical food, give it as a bolus through the tube (not in the feeding bag), and flush and check the tube regularly to be sure it is not degrading or blocked.

Missed doses: If you miss a dose, take it as soon as you remember, then space the remaining doses about 3 to 4 hours apart; if it is not possible to fit all doses into the day, skip the missed dose rather than taking extra or doubling the next dose.

Overdose: Taking more than prescribed mainly increases the chance of stomach pain, diarrhea, and vomiting; if a large extra dose is taken or significant symptoms develop, contact your healthcare provider, local emergency service, or poison control center right away for advice.

Common side effects: The most frequent side effects are gastrointestinal, including abdominal pain, diarrhea, vomiting, and nausea, which occur in many patients (often within the first several weeks), are usually mild to moderate, and sometimes require dose reduction or slower titration.

Serious or rare adverse effects: Problems with enteral feeding tubes (reduced flow, clogging, or breakdown of the tube material) have been reported, sometimes requiring tube replacement; severe or persistent vomiting or diarrhea may lead to dehydration or poor nutrition and need prompt medical attention; allergic reactions are uncommon but signs such as rash, swelling, or trouble breathing require emergency care.

Warnings and precautions: Do not use Dojolvi in patients with pancreatic insufficiency, because they may not absorb the medicine effectively; avoid use in PVC feeding tubes and monitor any feeding tube regularly for integrity; safety experience includes infants through adults, but dosing and monitoring in very young children should be managed by specialists; it is not known if Dojolvi is safe in pregnancy or whether it passes into breast milk, so decisions during pregnancy and breastfeeding should be individualized with the metabolic and obstetric teams.

Relative safety profile: Compared with many systemic drugs, Dojolvi acts mainly as a specialized dietary fat, with its main risks being gastrointestinal upset and device‑related problems rather than direct liver, kidney, or heart toxicity, although standard metabolic and nutritional monitoring is still important.

Side‑effect reporting and safety updates: Patients and caregivers should report troublesome side effects to their healthcare provider and may also report them directly to the FDA MedWatch program (by phone or online) or to the manufacturer using the number on the medication guide, where updated safety information is also made available.

Drug and supplement interactions: The key known interaction is with pancreatic lipase inhibitors (such as orlistat), which can reduce absorption and effectiveness of Dojolvi and are generally avoided; no specific interactions have been documented with most other prescription drugs, OTC medicines, vitamins, or herbal products, but all medications and supplements should be reviewed with the metabolic team before and during treatment.

Food, alcohol, and diet: Dojolvi must always be mixed into soft food, liquid, or formula before taking and is usually given with a low‑fat, carefully planned LC‑FAOD diet; there are no strict food prohibitions beyond the prescribed diet, but alcohol can worsen metabolic control or dehydration and should be limited or avoided according to specialist advice.

Procedures and imaging: No specific interactions are known with radiology contrast agents or common anesthetic drugs, but anyone performing surgery, sedation, or major procedures should know the patient has LC‑FAOD and is taking Dojolvi so that fasting, glucose support, and other precautions can be planned.

Precautions and monitoring: Dojolvi should not be used in people with pancreatic insufficiency because they may not break it down and absorb it properly; patients receiving it by feeding tube need ongoing checks that the tube is intact and functioning; clinicians typically monitor growth, weight, nutritional status, and metabolic labs periodically and may adjust the dose or diet if there are ongoing gastrointestinal symptoms or concerns about under‑ or over‑nutrition.

Q: What is Dojolvi used for?
A: Dojolvi is a prescription oral liquid fat used as a source of calories and fatty acids to help manage long‑chain fatty acid oxidation disorders (LC‑FAOD) in children and adults, alongside a carefully controlled diet and other standard treatments.

Q: How long will it take before I notice any benefit?
A: Some people notice improved energy or fewer day‑to‑day symptoms within weeks, but the main benefits—such as fewer metabolic crises, hospital visits, or episodes of muscle breakdown—are usually assessed over several months by your metabolic care team.

Q: How is Dojolvi different from regular MCT oil?
A: Regular MCT oil contains even‑chain fats that mainly provide energy, while Dojolvi contains an odd‑chain fat (C7) that not only supplies energy but also helps refill key components of the body’s energy cycle, which may better support metabolism in LC‑FAOD for some patients.

Q: Can I stop Dojolvi suddenly if I feel well?
A: Do not stop or change your dose on your own; because Dojolvi provides a planned portion of your daily calories and fatty acids, sudden changes can upset your metabolic control, so any adjustments should be made gradually and only with your specialist’s guidance.

Q: Is Dojolvi safe during pregnancy or breastfeeding?
A: It is not known whether Dojolvi can harm an unborn baby or pass into breast milk, so if you are pregnant, planning pregnancy, or breastfeeding, your metabolic and obstetric providers will weigh the benefits of continuing treatment against the unknown risks and may enroll you in a pregnancy safety study.

Q: What should I do if my child vomits soon after a dose?
A: If vomiting occurs right after a dose, contact your metabolic team for individualized instructions on whether and when to repeat the dose, and seek urgent care if vomiting is severe, persistent, or accompanied by signs of low blood sugar, muscle pain, or unusual sleepiness.

Storage: Store Dojolvi upright at room temperature (68°F to 77°F / 20°C to 25°C), do not freeze it, and do not keep it in containers, oral syringes, or cups made of polystyrene or polyvinyl chloride (PVC).

After opening and mixing: Use an opened bottle within 9 months or by the expiration date, whichever comes first, and store any prepared mixture in the refrigerator for no more than 24 hours before use.

Disposal: Throw away any unused mixture after 24 hours and any remaining product after it expires or reaches 9 months from opening; place it in the household trash (not down the sink or toilet) or follow local drug take‑back instructions if available.